MedPath

Prenatal Exercise and Cardiovascular Health (PEACH)

Not Applicable
Completed
Conditions
Pregnancy
Interventions
Other: Aerobic exercise
Registration Number
NCT02948439
Lead Sponsor
University of Alberta
Brief Summary

Maintenance of a healthy pregnancy depends on an appropriate adaptation and responsiveness of blood vessels, to ensure appropriate blood flow to the fetus during everyday stressors. Previous work by the investigators has demonstrated that during pregnancy, the part of the nervous system responsible for cardiovascular function (the sympathetic nervous system) is hyperactive. The investigators also know that in women who develop high blood pressure during pregnancy that sympathetic nervous system activity is even higher. Yet, very little is known about why this occurs and how this might be affected.

Pregnant women are encouraged to be active, yet, less than 15% of women perform sufficient exercise to meet current guidelines. This is important because hyperactivity of the sympathetic nervous system is observed in other inactive populations and has been linked to adverse cardiovascular health outcomes including hypertension, atherosclerosis, heart attack, and stroke. Indeed, in 2011, the American Heart Association stated that inactivity was a risk factor as potent as cigarette smoking for the development of future cardiovascular disease in women.

The investigators' work and others have demonstrated that exercise during pregnancy is beneficial for both the mom and baby; however, the effect of prenatal exercise on neurovascular function is not known. If exercise is effective in controlling the increase in sympathetic activity that occurs during pregnancy, or its effects on the cardiovascular system, this may help prevent the development of high blood pressure or other cardiovascular problems during pregnancy.

Detailed Description

The objectives of this study are to: 1) examine the impact of exercise on sympathetic and vascular function during pregnancy; 2) examine the role of endothelial function on the vascular effects of exercise during pregnancy.

Study design:

100 women (\>18yrs) will be recruited in the first or second trimester (\<20 wks). Women with multiple pregnancies will be excluded. Eligible women will be randomized between an aerobic exercise intervention (EXER) or no intervention (CTRL).

Initial testing will take place between 16-20 weeks of pregnancy. Following initial baseline testing, women will be randomly assigned to an exercise intervention or no intervention. Women will receive an opaque sequentially numbered envelop with their allocation. Allocation will be determined using a randomly generated allocation sequence by an individual not associated with the research study. The intervention will consist of aerobic exercise equivalent to 50-70% of heart rate reserve, 3-4 times per week until the end of the study (34-36 weeks). For initial baseline testing (16-20 weeks) and at the end of the intervention (34-36 weeks), participants will visit the laboratory twice

On Day 1, participants will complete a peak exercise test on the treadmill or bike to volitional fatigue to measures fitness and cardiovascular/cerebrovascular responses to exercise.

On Day 2 Participants will arrive fasted (12 hrs) and blood samples will be collected. Anthropometrics, personal/familial history of hypertension and pregnancy complications will be recorded. Following a standardized breakfast, participants will undergo an assessment of reflex neurovascular control including a cold pressor test, flow mediated dilation and end expiratory voluntary breath hold. Muscle sympathetic nerve activity, ultrasound (blood flow and diameter of brachial, femoral and carotid arteries), blood pressure, heart rate and respiratory variables will be measured.

OUTCOME/IMPACT

Pregnancy is a stress-test for life; with women who develop complications during pregnancy having a higher risk for cardiovascular disease later in life. Exercise is well known to prevent cardiovascular disease through improvements in endothelial function and the sympathetic nervous system. Whether this improvements is also seen in pregnancy remains to be seen.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
64
Inclusion Criteria
  • >18 years old
  • singleton pregnancy
  • cleared to exercise by health care provider using Par Med X for Pregnancy (CSEP)
Read More
Exclusion Criteria
  • multiple gestation
  • absolute contraindication to exercise (CSEP)
  • <18 years old
  • develops any contraindication during intervention
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Exercise InterventionAerobic exerciseThe aerobic exercise intervention will consist of a walking program at 50-70% of individual heart rate reserve. This will begin at 16-20 weeks gestation and continue 3-4 times per week until the end of the study (34-36 weeks). The duration of exercise will increase each week up to a maximum of 40 minutes (5 min warm up, 25 minutes exercise, 5 min cool down). Women will have at least one supervised exercise session per week. The investigators will also monitor other activity using questionnaires and accelerometry. This will occur at baseline (16-20 weeks), mid-intervention (24-26 weeks) and at the end (34-36 weeks).
Primary Outcome Measures
NameTimeMethod
Sympathetic Nerve Activity - cold pressor test response16-20 weeks and 34-36 weeks gestation

Response of the sympathetic nervous system to cold pressor test (% change in activity)

Secondary Outcome Measures
NameTimeMethod
fetal outcomes- lengthwithin one month postpartum

Participants will provide the investigators with birth length for the infant (cm).

fetal outcomes- gestational agewithin one month postpartum

Participants will provide the investigators with gestational age at delivery (weeks).

maternal outcomes- mode of deliverywithin one month postpartum

Participants will provide the investigators with mode of delivery (vaginal or cesarean).

maternal outcomes- delivery complicationswithin one month postpartum

Participants will provide the investigators with information regarding any delivery complications.

maternal outcomes- gestational weight gainwithin one month postpartum

Participants will provide the investigators with the last maternal weight immediately before delivery. This will be used to calculate gestational weight gain (kg; last maternal weight - self reported pre-pregnancy weight).

Endothelial Function - time to peak dilation16-20 weeks and 34-36 weeks gestation

The investigators will assess endothelial function using flow mediated dilation (FMD, time to maximal dilation; s)

Respiratory measures - respiratory frequency16-20 weeks and 34-36 weeks gestation

Breathing frequency (breaths per minute). Measured using spirometry.

Food log16-20 weeks and 34-36 weeks gestation

The investigators will objectively measure nutrients in diet using a three day food record. This is completed through Food Prodigy/ Food Processor software.

Respiratory measures - oxygen16-20 weeks and 34-36 weeks gestation

Oxygen metabolism (% oxygen used per breath). Measured using a gas analyzer.

Sympathetic Nerve Activity - breath hold response16-20 weeks and 34-36 weeks gestation

Response of the sympathetic nervous system to voluntary breath hold (% change in activity)

Cerebral blood flow during exercise16-20 weeks and 34-36 weeks gestation

Brain blood flow in the middle cerebral artery during the acute incremental peak exercise test (cm/s). Measured using transcranial doppler ultrasound.

fasted blood sample - blood volume16-20 weeks and 34-36 weeks gestation

Fasted blood samples (\~30ml) will be analyzed for markers of blood volume (hematocrit; %)

fasted blood sample- epigenetics16-20 weeks and 34-36 weeks gestation

Fasted blood samples (\~30ml) will be analyzed for epigenetics (optional).

Cerebral blood flow at rest16-20 weeks and 34-36 weeks gestation

Brain blood flow in the middle cerebral artery at rest (cm/s). Measured using transcranial doppler ultrasound.

Respiratory measures - lung volume16-20 weeks and 34-36 weeks gestation

Total Lung Capacity (Liters). Measured using spirometry.

Cerebral autoregulation16-20 weeks and 34-36 weeks gestation

Brain blood flow in the middle cerebral artery in response to standing (cm/s). Measured using transcranial doppler ultrasound.

fasted blood sample- inflammatory markers16-20 weeks and 34-36 weeks gestation

Fasted blood samples (\~30ml) will be analyzed for inflammatory markers (i.e. C-Reactive Protein).

fasted blood sample- metabolic16-20 weeks and 34-36 weeks gestation

Fasted blood samples (\~30ml) will be analyzed for metabolic parameters (i.e. glucose)

fetal outcomes- NICUwithin one month postpartum

Participants will provide the investigators with information regarding length (days) of admission to Neonatal Intensive Care Unit (NICU) if applicable.

Endothelial Function- flow mediated dilation16-20 weeks and 34-36 weeks gestation

The investigators will assess endothelial function using flow mediated dilation (change in diameter; mm)

Respiratory measures - tidal volume16-20 weeks and 34-36 weeks gestation

Tidal Volume (Liters per breath). Measured using spirometry.

fetal outcomes- birth weightwithin one month postpartum

Participants will provide the investigators with birth weight for the infant (grams).

Respiratory measures - carbon dioxide16-20 weeks and 34-36 weeks gestation

Carbon Dioxide production (% carbon dioxide per breath). Measured using a gas analyzer.

fasted blood sample- sex hormones16-20 weeks and 34-36 weeks gestation

Fasted blood samples (\~30ml) will be analyzed for sex hormones (estrogen, progesterone, testosterone).

fasted blood sample - neurotransmitters16-20 weeks and 34-36 weeks gestation

Fasted blood samples (\~30ml) will be analyzed for sympathetic nervous system neurotransmitters (Norepinephrine, Epinephrine, Neuropeptide-Y).

maternal outcomes- pregnancy complicationsany time during study

Participants will provide the investigators with information regarding any pregnancy complications (gestational diabetes, pregnancy induced hypertension, preeclampsia).

Depression rating16-20 weeks and 34-36 weeks gestation

Participants will answer a 10-question questionnaire regarding their mood. A score of 10 or higher is indicative of depressive symptoms. The investigators will report the over number of women in each group who have a score of 10+ at the start and end of the intervention.

fetal outcomes- apgar scorewithin one month postpartum

Participants will provide the investigators with APGAR scores (out of 10) for the infant

Endothelial Function - shear stress16-20 weeks and 34-36 weeks gestation

The investigators will assess endothelial function using flow mediated dilation (shear stress; pascals).

Accelerometry16-20 weeks and 34-36 weeks gestation

The investigators will objectively measure physical activity using an accelerometer for one week. Average number of minutes per day spent in various activity levels will be determined.

Physical Activity Questionnaire16-20 weeks and 34-36 weeks gestation

The participants will report physical activity using the pregnancy physical activity questionnaire (gives metabolic equivalent hours per week (MET-hr/week).

Sleep Quality16-20 weeks and 34-36 weeks gestation

Participants will report their sleep quality using the Pittsburgh Sleep Quality index. A score of 5 or more indicates poor sleep quality. The investigators will compare this score between groups before and after the intervention.

Trial Locations

Locations (1)

Program for Pregnancy and Postpartum Health, University of Alberta

🇨🇦

Edmonton, Alberta, Canada

© Copyright 2025. All Rights Reserved by MedPath